company background image
1801 logo

Innovent Biologics SHSC:1801 Stock Report

Last Price

HK$36.00

Market Cap

HK$58.4b

7D

-15.6%

1Y

-6.5%

Updated

23 Mar, 2024

Data

Company Financials +

Innovent Biologics, Inc.

SHSC:1801 Stock Report

Market Cap: HK$58.4b

1801 Stock Overview

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.

1801 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Innovent Biologics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Innovent Biologics
Historical stock prices
Current Share PriceHK$36.00
52 Week HighHK$49.80
52 Week LowHK$27.30
Beta0.17
1 Month Change-10.00%
3 Month Change-6.01%
1 Year Change-6.49%
3 Year Change-52.38%
5 Year Changen/a
Change since IPO-36.95%

Recent News & Updates

Recent updates

Shareholder Returns

1801HK BiotechsHK Market
7D-15.6%-6.3%-0.7%
1Y-6.5%-42.8%-13.4%

Return vs Industry: 1801 exceeded the Hong Kong Biotechs industry which returned -42.8% over the past year.

Return vs Market: 1801 exceeded the Hong Kong Market which returned -13.4% over the past year.

Price Volatility

Is 1801's price volatile compared to industry and market?
1801 volatility
1801 Average Weekly Movement9.6%
Biotechs Industry Average Movement10.0%
Market Average Movement7.3%
10% most volatile stocks in HK Market14.7%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 1801 has not had significant price volatility in the past 3 months.

Volatility Over Time: 1801's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20114,872Michael Yuhttps://www.innoventbio.com

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23.

Innovent Biologics, Inc. Fundamentals Summary

How do Innovent Biologics's earnings and revenue compare to its market cap?
1801 fundamental statistics
Market capHK$58.41b
Earnings (TTM)-HK$1.11b
Revenue (TTM)HK$6.71b

8.7x

P/S Ratio

-52.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1801 income statement (TTM)
RevenueCN¥6.21b
Cost of RevenueCN¥1.81b
Gross ProfitCN¥4.40b
Other ExpensesCN¥5.43b
Earnings-CN¥1.03b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.63
Gross Margin70.89%
Net Profit Margin-16.56%
Debt/Equity Ratio28.1%

How did 1801 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.